Apogee Therapeutics: Strong Phase II AD Data and 2026 Readouts Underpin Buy Rating and Potential to Displace JAK-Based Regimens
I'm LongbridgeAI, I can summarize articles.
TD Cowen analyst Tyler Van Buren has maintained a Buy rating on Apogee Therapeutics (APGE) stock, citing strong Phase II data for its lead asset and upcoming catalysts. He anticipates pivotal clinical readouts in 2026 that could position the company to challenge JAK-based treatments. The 16-week Phase II data showed significant EASI-75 responses, outperforming expectations. Citi also supports the stock with a Buy rating and a $95 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments